Heart Transplant: When Advanced Heart Failure Requires a Donor Heart

A heart transplant is considered when a person’s heart has become so severely damaged that conventional treatment can no longer provide an adequate circulation or an acceptable quality of life.

Unlike coronary angioplasty, bypass surgery, valve replacement or pacemaker implantation, a heart transplant does not repair the patient’s existing heart.

It replaces the failing heart with a donor heart.

That makes transplantation fundamentally different from most other cardiac procedures.

The difficult part is not simply performing the operation. A patient must first be assessed to determine whether transplantation is appropriate, whether the potential benefits justify the risks, whether other treatments can still provide adequate support, and whether the patient can safely undergo lifelong immunosuppression.

Harrison’s describes cardiac transplantation as an established treatment for appropriately selected patients with advanced heart failure who are otherwise suitable candidates.

What is a heart transplant?

A heart transplant is an operation in which a diseased recipient heart is replaced with a donor heart.

The donor heart is surgically connected to the recipient’s:

• great vessels
• pulmonary circulation
• systemic circulation
• atrial structures

The transplanted heart then becomes responsible for maintaining the recipient’s circulation.

Modern transplantation commonly uses an orthotopic bicaval technique, in which the donor heart is placed in the normal anatomical position and the major vessels and venae cavae are connected to the recipient’s circulation.

The patient’s original heart is generally removed during the transplant operation, although specific surgical circumstances can vary.

Why would someone need a heart transplant?

The usual reason is advanced heart failure that remains severe despite appropriate treatment.

Heart failure can result from many diseases, including:

• ischemic cardiomyopathy
• dilated cardiomyopathy
• advanced valvular heart disease
• congenital heart disease
• restrictive or infiltrative cardiomyopathies
• certain genetic cardiomyopathies
• severe myocarditis-related cardiac dysfunction

Harrison’s describes advanced heart failure as a syndrome in which conventional treatment becomes insufficient and patients may have severe symptoms, repeated hospitalisation, poor cardiac reserve, low cardiac output and other evidence of progressive disease.

The important distinction is that having a low ejection fraction alone does not automatically mean that a person needs a transplant.

The transplant question is much broader.

Doctors consider the severity of heart failure, symptoms, exercise capacity, end-organ function, pulmonary circulation, other illnesses and whether alternative treatments remain effective.

When is heart failure considered advanced?

Advanced heart failure may be suspected when a patient continues to have significant limitations despite guideline-directed treatment and other appropriate interventions.

Possible features include:

• persistent severe symptoms
• recurrent hospital admissions
• worsening exercise capacity
• inability to tolerate important heart-failure therapies
• progressive kidney or liver dysfunction related to poor circulation
• low cardiac output
• recurrent need for intravenous inotropic support
• dependence on mechanical circulatory support

Harrison’s describes advanced heart failure as a state of refractory disease in which treatment may shift toward mechanical circulatory support or cardiac transplantation.

Importantly, transplantation is generally considered before irreversible deterioration of other organs makes the operation excessively hazardous.

Does every patient with severe heart failure qualify?

No.

Heart transplantation requires careful candidate selection.

The transplant team considers several broad areas.

Severity of heart disease

The underlying cardiac disease must be sufficiently advanced to justify transplantation.

Other medical conditions

Kidney disease, liver disease, cancer, vascular disease, infection, obesity, frailty and other conditions may affect candidacy.

Pulmonary circulation

Severe and irreversible pulmonary vascular disease can make transplantation considerably more difficult because the new right ventricle may be unable to cope with the pulmonary circulation.

Harrison’s specifically identifies pulmonary vascular resistance and transpulmonary pressure as important components of transplant assessment.

Functional status

Exercise capacity and cardiopulmonary testing can help determine how severely the heart failure is limiting the patient.

Ability to manage long-term treatment

After transplantation, the patient must take immunosuppressive medication and attend regular medical follow-up.

The assessment therefore extends beyond the heart itself.

What happens during a transplant evaluation?

A transplant evaluation is comprehensive.

Depending on the patient and transplant centre, assessment may include:

• detailed cardiac history
• physical examination
• echocardiography
• cardiac catheterisation
• pulmonary pressure assessment
• cardiopulmonary exercise testing
• blood tests
• kidney and liver evaluation
• infectious disease screening
• cancer screening where appropriate
• assessment of other organ systems
• evaluation of nutritional status
• medication review
• psychosocial assessment

The purpose is to answer several questions:

How sick is the heart?

Could another treatment still provide adequate support?

Can the patient safely undergo transplantation?

Will the patient be able to manage lifelong post-transplant care?

What if a patient is too sick to wait for a donor heart?

Some patients deteriorate while waiting for transplantation.

Mechanical circulatory support may be used in selected patients.

One important example is a left ventricular assist device (LVAD).

An LVAD can help pump blood from the left ventricle into the systemic circulation.

Depending on the clinical situation, mechanical support may be used:

• as a bridge to transplantation
• as longer-term therapy when transplantation is not appropriate
• as temporary support while doctors determine the patient’s treatment pathway

Harrison’s describes LVAD therapy as an important component of advanced-heart-failure management and discusses its use as a bridge to transplantation, destination therapy and, in selected circumstances, a bridge to decision.

This means that a patient can sometimes be supported mechanically while waiting for a suitable donor heart rather than simply deteriorating without circulatory support.

What happens while waiting for a donor heart?

A patient who is accepted for transplantation enters an organ-allocation system.

The exact rules vary by country and transplant system.

Generally, allocation takes account of factors such as:

• medical urgency
• compatibility
• donor and recipient characteristics
• geographical considerations
• available organs
• the patient’s clinical status

Harrison’s describes allocation as incorporating urgency and donor-recipient considerations, with additional assessment of blood group, size compatibility and sensitisation.

Patients may remain at home while waiting, whereas those requiring intensive support may remain hospitalised.

The waiting period is therefore not simply a passive period.

The transplant team continues to monitor the patient’s:

• heart failure
• kidney function
• pulmonary pressures
• infections
• nutritional status
• mechanical support where applicable
• overall ability to proceed with transplantation

Why is blood-group and immune compatibility important?

The donor heart contains cells carrying biological markers that can be recognised as foreign by the recipient’s immune system.

The recipient’s immune response can attack the transplanted organ.

Blood-group compatibility is therefore important.

Some patients also have pre-existing antibodies that can react against donor tissue.

Harrison’s describes the use of prospective or virtual crossmatching in sensitised patients to assess immunological compatibility before accepting a donor heart.

This is one reason why finding a suitable donor heart is not simply a matter of finding any available heart.

What happens when a donor heart becomes available?

Once a potential donor heart is identified, the transplant team evaluates whether it is appropriate for the recipient.

Considerations can include:

• blood-group compatibility
• donor-recipient size
• donor heart function
• donor medical history
• evidence of cardiac disease
• recipient urgency
• immunological considerations
• transportation time

The donor heart must be retrieved and transported under carefully controlled conditions.

The time outside the body is limited because prolonged ischaemia can damage the organ.

Modern organ-preservation and ex-vivo perfusion techniques have also expanded the ability to evaluate and, in selected situations, recondition donor hearts. Harrison’s discusses these approaches as part of efforts to expand the donor pool.

How is heart transplant surgery performed?

Heart transplantation is major open-heart surgery.

The operation is performed under general anaesthesia and uses cardiopulmonary bypass to maintain circulation while the diseased heart is removed and the donor heart is implanted.

In a modern bicaval orthotopic transplant:

1. The recipient is placed on cardiopulmonary bypass.
2. The diseased heart is removed.
3. The donor heart is positioned in the recipient’s chest.
4. The donor and recipient atrial structures are connected.
5. The superior and inferior vena cava are connected.
6. The pulmonary artery is connected.
7. The aorta is connected.
8. The transplanted heart is allowed to resume circulation.
9. The patient is gradually separated from cardiopulmonary bypass.

Harrison’s describes the bicaval orthotopic technique and the major anatomical connections involved in the operation.

What is different about the transplanted heart?

One important feature of a transplanted heart is that it is denervated.

The nerves that normally connect the heart directly with the autonomic nervous system are interrupted during transplantation.

Harrison’s describes this surgical denervation and its implications for early postoperative physiology and heart-rate responses.

This does not mean that the transplanted heart cannot function normally.

The heart can adapt to the recipient’s circulation and provide effective cardiac output.

However, its regulation differs from that of a native heart.

What is rejection?

The immune system recognises the transplanted heart as foreign.

Without immunosuppression, the recipient’s immune system can attack the donor heart.

This process is called rejection.

Rejection can occur in different forms and at different times after transplantation.

The transplant team therefore monitors for evidence of rejection even when the patient feels well.

The treatment and surveillance strategy depends on the type and severity of rejection and the patient’s overall condition.

Why are immunosuppressive medicines necessary?

Immunosuppressive medicines reduce the immune response against the transplanted heart.

A typical regimen combines medicines acting through different immune pathways.

Harrison’s describes combination immunosuppression using a calcineurin inhibitor, corticosteroid and an antiproliferative or related agent, while noting that the exact regimen is adjusted according to the individual patient’s circumstances.

The goal is a balance:

Too little immunosuppression → increased risk of rejection.

Too much immunosuppression → increased risk of infection, drug toxicity and malignancy.

This balance continues for the entire life of the transplant recipient.

How is rejection monitored?

Monitoring may involve:

• clinical assessment
• echocardiography
• blood tests
• electrocardiography
• assessment of biomarkers where appropriate
• imaging
• endomyocardial biopsy in selected settings

Harrison’s describes endomyocardial biopsy as an important tool in the development and monitoring of cardiac transplantation and rejection.

Modern transplant programs may combine biopsy-based and non-invasive surveillance depending on the centre, time after transplant and individual risk.

What infections can occur after transplantation?

Immunosuppression increases susceptibility to infection.

The risk changes over time.

Early after transplantation, bacterial and surgical-site infections are important concerns.

Later, opportunistic infections become more relevant.

Harrison’s describes infections involving organisms such as CMV, EBV, Aspergillus, Toxoplasma and Pneumocystis among important infectious complications in transplant recipients.

CMV remains particularly important because it can produce systemic disease and affect transplant outcomes.

For this reason, transplant programs use combinations of:

• infection screening
• vaccination planning
• antimicrobial prophylaxis where appropriate
• laboratory surveillance
• prompt treatment of suspected infection

What is cardiac allograft vasculopathy?

One of the distinctive long-term complications of heart transplantation is cardiac allograft vasculopathy (CAV).

It is a form of diffuse disease affecting the coronary arteries of the transplanted heart.

Unlike typical coronary atherosclerosis, CAV can involve widespread vascular changes throughout the coronary circulation.

Harrison’s describes CAV as an important late complication of cardiac transplantation and explains that immunological and non-immunological factors contribute to its development.

Because the transplanted heart is denervated, coronary disease may not necessarily produce the classic angina symptoms that a person with a native heart might experience.

This makes surveillance particularly important.

Can the transplanted heart develop other diseases?

Yes.

The transplanted heart remains susceptible to problems including:

• rejection
• infection
• coronary allograft vasculopathy
• arrhythmias
• valve disease
• ventricular dysfunction
• medication-related complications

In addition, long-term immunosuppression can contribute to:

• kidney dysfunction
• hypertension
• metabolic abnormalities
• increased infection risk
• certain malignancies

Harrison’s specifically identifies renal dysfunction and malignancy among important long-term complications of transplantation.

What is recovery like after a heart transplant?

Recovery occurs in stages.

Initially, the patient remains in intensive care for close monitoring.

The team assesses:

• cardiac function
• blood pressure
• rhythm
• bleeding
• kidney function
• respiratory function
• infection
• response to immunosuppression

As the patient stabilises, intensive-care support is reduced.

Rehabilitation then becomes increasingly important.

This can include:

• gradual mobilisation
• breathing exercises
• nutritional support
• physical rehabilitation
• medication education
• infection-prevention education
• preparation for discharge

The exact length of hospitalisation varies considerably between patients.

What is life like after a heart transplant?

A transplant is not the end of medical treatment.

It begins a different form of long-term care.

Patients generally require:

• lifelong immunosuppression
• regular transplant-clinic follow-up
• medication monitoring
• surveillance for rejection
• infection prevention
• monitoring of kidney function and metabolic health
• cardiovascular surveillance
• cancer screening
• physical rehabilitation and healthy lifestyle measures

Medication adherence is particularly important.

Missing immunosuppressive medication can increase the risk of rejection.

Can someone exercise after a heart transplant?

Physical activity is generally an important component of rehabilitation after transplantation once the transplant team considers it appropriate.

The type and intensity of exercise depend on:

• recovery from surgery
• graft function
• complications
• overall fitness
• other medical conditions

Exercise should therefore progress under appropriate medical guidance rather than being determined solely by the fact that a transplant has occurred.

Is a heart transplant a cure?

It is more accurate to think of transplantation as replacement of a failing heart followed by lifelong management, rather than a permanent cure.

The original heart disease may no longer affect the transplanted heart in the same way, but the recipient now faces different long-term issues.

These include:

• rejection
• immunosuppression
• infection
• CAV
• renal complications
• malignancy
• other medication-related problems

The transplant therefore changes the patient’s disease pathway rather than eliminating the need for medical care.

Heart transplant vs LVAD

For some patients with advanced heart failure, the major question is not simply whether transplantation is needed.

It may be whether transplantation or mechanical circulatory support is the appropriate long-term strategy.

These are not interchangeable treatments for every patient.

The appropriate pathway depends on the patient’s cardiac disease, other medical conditions, transplant eligibility, mechanical-support suitability and local specialist assessment.

Harrison’s describes mechanical circulatory support as an important alternative or bridge in advanced heart failure.

What about children with congenital heart disease?

Heart transplantation is also relevant to selected children with severe congenital heart disease or advanced ventricular failure.

However, pediatric transplantation involves additional considerations related to:

• growth
• congenital anatomy
• previous operations
• pulmonary vascular disease
• immunological factors
• psychosocial development
• lifelong transition from pediatric to adult care

This is one reason the Pediatric Heart Surgery article in this cluster should not be treated as interchangeable with heart transplantation.

Surgery may repair congenital anatomy, while transplantation may become necessary only when conventional reconstruction or medical treatment can no longer provide adequate cardiac function.

What questions should a patient ask a transplant team?

Before entering or progressing through a transplant program, useful questions include:

1. Why is transplantation being considered in my case?
2. What alternatives remain available?
3. Am I being evaluated for an LVAD or other mechanical support?
4. What tests are required before listing?
5. What factors could prevent transplantation?
6. How is donor compatibility assessed?
7. What happens if my condition deteriorates while I am waiting?
8. What type of transplant operation is planned?
9. What immunosuppressive medicines will I need?
10. How will rejection be monitored?
11. What infections and other complications will I need to watch for?
12. How often will I need follow-up after transplantation?
13. What restrictions will apply during recovery?
14. What long-term monitoring will I need?

The key point

A heart transplant is reserved for a carefully selected group of patients with advanced cardiac disease.

The pathway begins long before the operation.

It involves determining whether heart failure has reached an advanced stage, evaluating whether other treatments remain appropriate, assessing the patient’s other organs and overall suitability, and considering mechanical circulatory support when necessary.

If a suitable donor heart becomes available, the diseased heart can be replaced through orthotopic transplantation.

But the operation is only the beginning.

The recipient then requires lifelong immunosuppression and surveillance for rejection, infection, cardiac allograft vasculopathy and other complications.

For the right patient, transplantation can fundamentally change the course of advanced heart failure—but it requires a lifelong partnership between the patient and a specialised transplant team.

Written and Reviewed By Dr. Munaf Ahmad Ansari

Medical information note: This article is written for information purpose only. Individual treatment decisions should be based on contemporary clinical guidelines and assessment by an appropriately qualified medical team.